pathological variables, including sex of the patients, presence of metachronous cancer, size, T staging, presence of distant metastases, and positivity of microsatellite instability (MSI) in the cancer (p < 0.05). FAM134B mRNA and protein expression was decreased in FAM134B mutated cancers. To conclude, FAM134B mutation is common in colorectal cancer. The association of the mutation of this gene with adverse clinical and pathological parameters is congruent with the tumour suppressive properties of the gene.
Introduction
FAM134B (Family with sequence similarity 134, member B) also called JK1 belongs to a family of three genes (FAM134A, FAM134B, and FAM134C) , located at 5p15.1, which was discovered using comparative genomic hybridization analysis (Tang et al. 2001 (Tang et al. , 2007 . Human FAM134B cDNA encodes a 497-amino-acid cis-Golgi transmembrane protein consisting of a C-terminal coiled-coil domain and two long hydrophobic segments, which are essential for long-term survival of nociceptive and autonomic ganglion neurons (Kurth et al. 2009 ). Altered expression of the FAM134B gene is also involved with vascular dementia and allergic rhinitis (Kong et al. 2011; Melchiotti et al. 2014) . Another study revealed that FAM134B regulated endoplasmic reticulum turnover by selective autophagy (Khaminets et al. 2015) . FAM134B is an ER-resident receptor protein that can bind to autophagy modifier microtubules-associated protein 1A/1B-light chain 3 (LC3) and gamma aminobutyric acid receptor-associated protein (GABARAP) and facilitate endoplasmic reticulum degradation (Khaminets et al. 2015) . It was also reported that suppression of FAM134B protein in human cells resulted an expansion 1 3 of ER structures, while upregulation caused endoplasmic reticulum fragmentation and lysosomal degradation (Kurth et al. 2009; Khaminets et al. 2015) . In addition, a recent study demonstrated that loss of FAM134B was associated with increased production of Ebola virus proteins GP and VP40 and higher accumulation of nucleocapsid lattices in mouse embryonic fibroblasts (Chiramel et al. 2016) .
In cancer, studies from our group reported that FAM134B is a growth-related gene and plays an important role in the pathogenesis of oesophageal and colorectal cancer (Kasem et al. 2014a, b, c; Islam et al. 2017; Haque et al. 2016) . In colorectal cancer, 57% of patients displayed FAM134B DNA copy number deletion, which was associated with advanced cancer stages (Kasem et al. 2014c) . It was also reported that FAM134B mRNA and protein expression was significantly downregulated in colorectal cancer tissues when compared to colonic adenoma (pre-invasive lesions) and non-cancer tissue samples (Kasem et al. 2014a) . A functional study revealed that FAM134 modulated the invasion and migration of colon cancer cells (Kasem et al. 2014b) . A more recent study indicated that FAM134B expression is stage-dependent and it suppresses the growth and proliferation of colon cancer both in vivo and in vitro (Islam et al. 2017) .
Mutations in FAM134B lead to production of mutant FAM134B protein which is unable to act as an autophagy receptor and causes sensory neuropathy in humans (Kurth et al. 2009; Khaminets et al. 2015) . Indeed, loss of function' mutations in FAM134B were first reported in hereditary sensory and autonomic neuropathy type IIB (HSAN IIB) (Kurth et al. 2009 ). Subsequently, a number of studies noted the presence of homozygous loss of function mutations in FAM134B in neuronal and vascular diseases (Kong et al. 2011; Davidson et al. 2012; Murphy et al. 2012; Ilgaz et al. 2014) . In addition, a recent study from our group reported novel mutations in FAM134B in patients with oesophageal squamous cell carcinoma with advanced pathological stages (Haque et al. 2016 ). However, mutational status of FAM134B and its clinicopathogenic associations remain completely unknown in colorectal cancer. As FAM134B copy number deletion, reduced mRNA, and protein expression were noted in advanced pathological stages of colorectal cancer, mutations may be another source of FAM134B downregulation in cancer tissues. Thus, this study aims to identify novel mutation sites and their impact on clinicopathological features in colorectal cancer.
Materials and methods

Patients and clinicopathological parameters
Tumour tissues and matched non-cancer tissues (taken from near the surgical resection margin) from the same patient who underwent resection of colorectal carcinomas by a colorectal surgeon (CTL) were prospectively collected during the period of 2012-2014 from hospitals in Queensland, Australia. The collected tissues were snap frozen in liquid nitrogen and stored at −80 °C. Patients were recruited consecutively during the study period with no selection bias. Tissues samples were excluded from the study if they were lacking adequate cancer mass or the patients did not come back for clinical follow-up. Ethical approval for this work has been obtained from the Griffith University Human Research Ethics Committee (GU Ref No: MSC/17/10/ HREC).
Histological sections were cut and stained with haematoxylin and eosin (H&E) for light microscopic examination. The pathological features of patients with colorectal cancer were analysed by examining the histological sections, and were graded, classified, and staged according to the World Health Organization (WHO) criteria (Hamilton et al. 2010) . Only adenocarcinoma was included in the study. After reviewing, 88 patients (46 women; 42 men) with colorectal adenocarcinomas were included for the analysis. The mean age of the patients used in this study was 69 years (range 24-91). The site and size (maximum length in mm) of the cancers were recorded. Proximal cancers were defined as cancer located in the caecum, ascending colon, and transverse colon, whereas distal cancers were defined as cancers found in the region of the descending colon, sigmoid colon, and rectum. 47% (n = 41) of colorectal cancer was located in proximal colon, while 53% (n = 47) was located in the distal colorectum. Among the 88 cases studied, 22% (n = 19) of the carcinomas had lymph node metastasis, whereas 88% (n = 69) of cancer patients had no lymph node metastasis. There were 11% (n = 10) stage I, 43% (n = 38) stage II, 22% (n = 19) stage III, and 24% (n = 21) stage IV carcinomas. A cryostat (Leica Biosystems, Mt Waverley, VIC, Australia) was used to section tissues from these patients for RNA and DNA extraction, with confirmation that they contained a representative cancer area. A schematic summary of the flow of the experiments is shown in Fig. 1 .
Clinical management
Clinical management was performed by a pre-agreed standardised multi-disciplinary protocol. The cancer tissues were investigated for microsatellite instability markers (by immunohistochemistry) and BRAF mutation status (by Sanger sequencing) according to the clinical guidelines. The use of post-operative adjuvant therapy was based on the pathological stage of the cancer. The follow-up period was defined as the interval between the date of surgery for colorectal carcinoma and the date of death or closing date of the study. The actuarial survival rate of the patients was calculated from the date of surgical resection of the colorectal carcinomas to the date of death or last follow-up. Only cancer-related death was counted as an end point in the statistical analysis. Persistence or recurrence of the disease was also recorded.
Cell culture
Three colon cancer cell lines (SW-480, SW-48, and HCT116) and one non-neoplastic colon epithelial cell line (FHC) were used in this study. All these cells were purchased from ATCC (American type culture collection) and maintained as previously described (Islam et al. 2017 ).
Extraction of DNA and RNA
Sections were cut for haematoxylin and eosin staining from the collected frozen tissues. The sections were examined by an anatomical pathologist (AKL) to confirm that cancer cells made up of more than 70% of the volume of the samples. Then, the selected fresh frozen tissues were sectioned into 7 μm slices for RNA and DNA extractions. DNA was extracted and purified from selected tissue sections with Qiagen DNeasy Blood & Tissue kits (Qiagen Pty. Ltd., Hilden, Germany) following the manufacturer's guide lines. DNA from cultured cells was also extracted using this kit. RNA was extracted from the fresh frozen tissue sections using miRNeasy Mini kits (Qiagen) according to the manufacturer's protocol. The purity of the extracted DNA and RNA was checked with the optical density (OD) method using a nanodrop spectrophotometer and the concentrations were noted in ng/μL.
Quantitative real-time PCR (qPCR) analysis
For quantitative PCR, first-strand cDNA was generated using DyNAmo™ cDNA Synthesis Kits (Qiagen) as previously described (Gopalan et al. 2010) . FAM134B mRNA expression changes in colorectal cancer tissues samples were examined using an IQ5 multicolour real-time polymerase chain reaction (PCR) detection system (Bio-Rad, Hercules, CA, USA). qPCR was performed in a total volume of 20 μL reaction mixture containing 10 µL of DyNAmo Flash SYBR green master mix (Bio-Rad), 1.5 µL of each 5 μmol/L primer, 3 μL of cDNA at 50 ng/μL, and 4 µL of 0.1% diethylpyrocarbonate (DEPC) treated water as previously described (Kasem et al. 2014a ). The PCR amplification efficiencies were normalized to that of multiple housekeeping genes, including beta actin, 18 s, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). GAPDH and β-actin were selected on the basis of consistent results in cancer tissues. Primers that were used in this study are given in supplementary data 1. Results were presented as relative expression ratios (expression of FAM134B normalized by internal control GAPDH and β-actin expression). Fold changes were calculated according to previously published protocol (Livak and Schmittgen 2001; Islam et al. 2017) . A fold change of more than 2 was considered as high FAM134B expression and a fold change of 2 or less was considered as low FAM134B expression.
High-resolution melt (HRM) curve analysis
Genomic DNA extracted from 88 cancers and matched noncancer tissues were used for HRM analysis to screen the possible mutations in FAM134B sequence. HRM curve analysis was performed followed by amplifying target sequences on the Rotor-Gene Q detection system (Qiagen) using the RotorGene ScreenClust HRM Software. Exons 1-9 of FAM134B were PCR amplified in a total reaction volume of 10 μL comprising 5 μL of 2X sensimix HRM master mix, 1 μL of 30 ng/μL genomic DNA, diethylpyrocarbonate (DEPC, RNase free) treated water 2, and 1 μL of each FAM134B primer. The thermal cycling protocol was the same as published previously (Haque et al. 2016) . Each PCR run included a negative (no template) control. The melt curve data were generated by increasing the reaction mix temperature from 65 to 85 °C for all assays, with temperature increase rate of 0.05 °C/s and recording fluorescence at each increment. 
Purification of PCR products and Sanger sequencing analysis
All the possible variants detected in HRM analysis were further checked with Sanger sequencing for identifying the possible mutations. Briefly, after HRM curve analysis, selected and specific PCR products were purified according to the manufacturer's protocols from the NucleoSpin ® Gel and PCR Clean-up kit (Macherey-Nagel, Bethlehem, PA, USA). The purified PCR products were then subjected to sequencing using Big Dye Terminator (BDT) chemistry Version 3.1 (Applied Biosystems, Foster City, CA, USA) under standardised cycling PCR conditions. The generated data were analysed at the Australian Genome Research Facility (AGRF) using a 3730xl Capillary sequencer (Applied Biosystems). Sequences were then analysed with the Sequence Scanner 2 software (Applied Biosystems).
In silico analysis
The Ensembl transcript ID ENST00000306320 (transcript variant 1 for FAM134B) was used when required by a method as input. All the variants were analysed using freely available bioinformatics tools, such as Mutation Taster with NCBI 37 and Ensembl 69 database release (Schwarz et al. 2014) , PROVEAN (protein variation effect analyser), and SIFT (sorting intolerant from tolerant) to evaluate the consequences of the identified mutations. The results were also compared with ExAc and 1000 Genomes variant databases. The cut-off value used for PROVEAN and SIFT were −2.5 and 0.05, respectively, for predicting the pathogenic/nonpathogenic variants in this study.
Immunofluorescence
To examine the impact of FAM134B mutation on protein expression in mutated and non-mutated tissue samples of colorectal cancer, immunofluorescence analysis was performed. After being de-waxed (xylene) and re-hydrated (alcohols and water), fresh frozen sections (4 μm) were blocked with peroxidase block solution (Dako Australia Pty. Ltd, Sydney, NSW, Australia). Then, the slides were incubated with rabbit FAM134B (Santa Cruz, Dallas, TX, USA) (1:150) antibody at 4 °C overnight. This was followed by 2 h of incubation with secondary antibody labelled with fluorescein isothiocyanate (FITC) (Sigma Aldrich) at room temperature. The slides were mounted with glass coverslips and then observed under a confocal microscope (Nikon A1R+, Nikon Inc., Tokyo, Japan).
Western blot analysis
Total proteins were extracted from fresh frozen tissue samples with lysis buffer (Bio-Rad, Gladesville, NSW, Australia). These were followed by homogenization and quantitation by absorbance spectrometry. Afterwards, total protein (30 μg) was separated by 15% SDS-PAGE (BioRad) and transferred to nitrocellulose membranes (BioRad). The membrane was then developed to detect protein bands according to our previously published protocol (Islam et al. 2017) . Expression of FAM134B protein was quantified and normalized to GAPDH with the Image J 1.48 software.
Statistical analysis
Comparisons between variable groups were analysed using the Chi-square test, likelihood ratio, and Fisher's exact test. All the data were entered into a computer database and the statistical analysis was executed using the Statistical Package for Social Sciences for Windows (version 24.0, IBM SPSS Inc., New York, NY, USA). Survival analysis was tested using the Kaplan-Meier method. Significance level was taken at p < 0.05.
Results
FAM134B mRNA expression in colorectal cancer tissues
The expression of FAM134B in cancer and matched nonneoplastic tissue samples was presented in Fig. 2a . The expression was statistically significant between the pairs of cancer and non-cancer tissue samples (p = 0.02). FAM134B expression in cancer tissues samples was lower compared to the corresponding non-cancer samples (0.85 ± 0.07 versus 0.97 ± 0.03).
We categorized FAM134B expression into high (fold change more than 2) and low (fold change 2 or less than 2) expression as only two cases showed normal expression (fold change in the range of 1-2). Among the colorectal cancers, 76% (n = 67/88) showed low FAM134B mRNA expression, whereas the remaining 24% (n = 21) had high FAM134B expression (supplementary data 2). The association of FAM134B mRNA expression with clinicopathological parameters was also analysed. The data are presented in supplementary data 2. It was noted that colorectal adenocarcinomas with BRAF mutation tended to have low FAM134B expression (p = 0.046). The median overall follow-up of patients with colorectal cancer was 47 months and the survival rates correlated with the pathological stages of cancer (p = 0.0001) (Fig. 2b) . Patients with colorectal cancer expressing low levels of FAM134B mRNA had shorter survival time when compared to those with high FAM134B mRNA expression (38 versus 47 months) (Fig. 2c) . However, the difference in survival time between the groups did not reach statistical significance (p = 0.41).
Identification of FAM134B mutations in colorectal tissue samples and cell lines
Variants in FAM134B sequence in tissues and cells samples were first suspected on the basis of distinctive melting curves in HRM analysis. The mutant HRM amplified products (exons 1-9) are presented in supplementary data 3.
In colorectal cancer, we noted 42 nucleotide variants in the complete coding (exons 1-9) region of FAM134B (Table 1 ; Fig. 3 ). Among these, 36 were identified as novel mutations. In addition, six variants (c.744C>T, c.1164A>G, c.1112T>C, c.1149A>G, c.1153G>C, and c.1107G>C), were noted which had previously been reported in oesophageal squamous cell carcinoma (Haque et al. 2016) . Of the 42 mutations, thirty-four were identified as substitution changes, while five were insertions (c.1130_1131insT, c.1160_1161insG, c.1155_1156insA, c.1176_1177A, and c.654_655insGG) and three deletions (c.1148_1148delT, c.1134_1134delT, and c.1138_1138delC) ( Table 1) . In matched non-cancer tissues, we identified eight mutations (Table 1 ). In addition, in colon cancer cell lines, we noted c.1112T>C, c.1149A>G, and c.944C>T variants (Fig. 4 and supplementary data 4) . Of the 42 variants identified, 37 were heterozygous and 5 were homozygous changes. Interestingly, the mutational variants c.1149A>G and c.1112T>C were found to be common in cancer, noncancer tissues, and cell lines of colon cancer origin. We also identified seven known single-nucleotide polymorphisms (SNPs) in the cancers (Supplementary data 5 and 6).
We noted 32 variants in the non-coding intronic sequence of FAM134B in colorectal cancer (Table 2) . Twenty-five of them were identified as novel in colorectal cancer, whereas seven (g.135916_135916delA, g.136084G>A, g.139115C>A, g.135963C>A, g.136122G>C, g.138869G>T, and g.139063_139063delT) were previously described in oesophageal squamous cell carcinoma (Haque et al. 2016) . Among these intronic variants, 23 were single-nucleotide substitutions, one (g.135871CG>TT) a double base substitution, two were insertions, and six were deletions (Table 2) . A single (g.139063_139063delT) deletion, in the intronic regions, was identified in non-cancer matched tissues, whereas no mutation was noted in the intronic regions of FAM134B in colon cancer cell lines.
Results of predictions using Mutation Taster, PROVEAN and SIFT, which primarily assess the consequences of nucleotide as well as amino-acid changes on protein features and functions, are listed in Tables 1  and 2 . More than 64% (27/42) of variants in the coding region of FAM134B were predicted as deleterious or damaging in colorectal cancer (Table 1) , whereas only 25% (8/32) of intronic mutations were noted as disease (Table 2 ). In non-cancer matched tissue samples, variants (p.Asp349Arg, p.Glu362Lys, p.Gly356Arg, and p.Asp349Arg) were predicted to be pathogenic (Table 1) . Among the known variants, p.Thr208Met and p.Val203Met were noted as damaging or deleterious (supplementary data 5). In addition, variant c.944C>T (p.Ser286Leu), which was identified in colon cancer cell lines, was predicted to be pathogenic (supplementary data 4).
FAM134B mutations associated with clinicopathological parameters in CRC
The association of FAM134B mutations with clinical and pathological factors of patients with colorectal cancer is shown in Table 3 . Approximately, 47% (41/88) of patients with colorectal cancer had FAM134B mutations. Significant correlation between FAM134B mutations with the presence of microsatellite instability (MSI) (p = 0.001) in colorectal cancer was detected. In addition, a significant (p = 0.043) association of metachronous colorectal cancer (defined as the presence of more than one primary carcinoma detected consequently in a single person and the second or subsequent cancer is not a recurrence or distant metastasis) (Lam et al. 2012) and FAM134B mutations was noted (Table 3) . Table 4 lists the relationship of clinicopathological variables with the mutations detected in different exons of FAM134B. Approximately, 8% (7/88) of colorectal cancer showed FAM134B mutation in exon 4. Variants identified in exon 4 (11/42) were significantly correlated with sex of the patients, presence of metachronous cancer, MSI positivity, and T stage (p = 0.013, 0.032, 0.024 and 0.014, respectively) of the cancer (Table 4) . More than 5% (5/88) of the cancer patients had FAM134B mutations positive in exon 5 (5/42). These mutations were significantly associated with positivity of MSI (p = 0.004) ( Table 4 ). Exon 7 mutation was detected in 12.5% (11/88) of the cancers. Mutation in exon 7 was associated with distant metastases (p = 0.048) and larger size (>40 mm) of the tumour (p = 0.044) ( Table 4) . FAM134B mutations were frequently seen in exon 9 as they were noted in 20.45% (18/88) of the cancers. The mutations were significantly correlated with age (p = 0.031) of the patients and location of the cancer (p = 0.031) ( Table 4) . Changes in cDNA, protein sequence, splice site alterations, and frameshift mutations were related with pathological variables (supplementary data 7).
Finally, we analysed the relationship between the prevalence of FAM134B mutations and patient survival (supplementary data 8). Patients with FAM134B mutations in exon 4 had In addition, patients with deletion mutations in introns had shorter survival times (41 versus 47 months) when compared to the non-mutated patients (supplementary data 8C). Nevertheless, the difference between these groups did not reach statistical significance level (p > 0.05). 
FAM134B mutations inhibit protein expression
FAM134B protein expression in mutation positive cancers (n = 10) and non-mutated cancers (n = 10) was examined by immunofluorescence microscopy. FAM134B protein expression in representative mutation positive cancer samples (7/10) was remarkably lower when compared to that of mutation negative samples (Fig. 5a, b) . A number of pathogenic mutations were detected in the selected cancer samples (sample IDs: 8, 20, 62, 96, 99, 117, and 125) , which exhibited reduced protein expression. In addition, very low FAM134B mRNA expression was noted in these samples (Fig. 5c ). In addition, colon cancer cells (cell lines SW480, SW48, and HCT116) having deleterious FAM134B mutations expressed lower levels of FAM134B protein and mRNA when compared to that of non-neoplastic colon epithelial (FHC) cells in immunofluorescence microscopic analysis (supplementary data 9). The reduction of FAM134B protein expression in mutated cancer tissues was confirmed by Western blot analysis in representative samples. Figure 5d , e presented the results from mutated cancer tissues (n = 7) and nonmutated matched non-cancer tissues (n = 2). Five patients (5/7) with colorectal cancer (sample IDs 20, 62, 99, 117, and 125) harbouring multiple mutations showed significant (p = 0.001) reduction of FAM134B protein expression when compared with cancers having no mutation (Fig. 5c,  d ). The protein band intensity of FAM134B expression in cancer samples (sample IDs 20, 62, 99, 117, and 125) were 0.126 ± 0.02, 0.137 ± 0.03, 0.058 ± 0.02, 0.07 ± 0.02, and 0.066 ± 0.01, respectively, whereas protein band intensity in the non-cancer tissues samples (sample IDs 1 and 17) was 0.899 ± 0.12 and 0.0908 ± 0.08, respectively. Colon cancer cell lines (SW480, SW48 and HCT116) showed notable downregulation of FAM134B protein expression when compared to that of the non-neoplastic colon epithelial (FHC) cell line (Supplementary data 10).
Discussion
Using data from the ICGC (international cancer genome consortium), FAM134B mutation can be identified in many cancers (https://dcc.icgc.org/). FAM134B mutation was noted in approximately 7% of human cancers. In the current study, we determined that approximately 47% (41/88) of colorectal cancers had FAM134B mutation. In these 41 patients, we have identified 42 exonic variants in colorectal cancer tissues and colon cancer cell lines, 36 of which were novel mutations (Table 1) . Among the 42 exonic variants, 29 were missense mutations which change the aminoacid sequences of FAM134B protein (Table 1 ). In computational analysis, we noted that eight frameshift mutations (p.Asp349ArgfsX13, p.Pro351HisfsX3, p.Thr359AsnfsX3, p.Met357AsnfsX5, p.Glu364ArgfsX9, p.Gln190GlyfsX63, p.Asn355MetfsX11, and p.Pro351HisfsX3) have the potential to cause non-sense-mediated mRNA decay (NMD), consequently, can produce a strongly truncated protein.
However, further functional studies with the identified variants (especially with predicted pathogenic variants) are needed to confirm their roles in producing NMD or generating truncated proteins. The remaining five variants (p.Glu354Glu, p.Thr359Thr, p.Gly358Gly, p.Gly211Gly, and p.Phe178Phe) were identified as silent or synonymous mutations (no change in amino acid) in colorectal cancer. Mutations in FAM134B associated with non-malignant conditions were previously detected in exon 1 and intron 7. By contrast, in colorectal cancer, most of the mutations were located in exons 4, 5, 7, or 9. Similarly, in oesophageal cancer, FAM134B mutations were also detected in exons 4, 5, 7, or 9 (Haque et al. 2016) . Thus, variants in FAM134B appear to be restricted to specific regions of the gene in cancer and might be playing a key role in carcinogenesis.
In the current study, FAM134B mutations in exon 4 were significantly associated with the sex of the patients (p = 0.013) with colorectal cancer. About 15% of female samples (7/46) showed FAM134B exon 4 mutations in patients with colorectal carcinoma. Mutations in tumour suppressors, such as p53, BRCA1, BRCA2, WT1, or ATM genes, which maintain genetic stability, are more common in women and correlations were noted in different cancers (Buchholz et al. 1999; Lai et al. 2002; Rivera et al. 2007 ). For example, Rivera et al. have reported that heterozygous mutations of an uncategorized gene FAM123B in female patients were associated with X chromosome-mediated inactivation of tumour suppressor WT1 in Wilms tumours (Rivera et al. 2007 ). Thus, FAM134B exon 4 mutations in female patients with colorectal cancer may be involved with the modulation of other regulatory gene(s) in the activation of genes on the X chromosome which may, in turn, lead to the inactivation of the FAM134B gene by a singlehit mechanism. Therefore, further research using genomewide scanning with large cohorts is needed to unveil the exact role of FAM134B in maintaining genetic integrity, especially in the female population.
FAM134B mutations (exon 4) were noted to be correlated with the T stage of CRC (p = 0.014). Late stage cancers more often had FAM134B exon 4 mutations when compared to early stage cancers. Similarly, patients with larger tumour (>40 mm) in their colorectum exhibited a high frequency of FAM134B mutation in exon 7 (p = 0.044) ( Table 4 ). In addition, mutations in exon 7 correlated with the presence of distant metastasis in colorectal cancer (p = 0.048). In addition, we observed that patients with cancer having exon 9 mutations or exon 4 mutations had poorer prognosis (supplementary data 8A and 8B). Furthermore, it was noted that disease causing mutations (deletions) in the introns had an impact on patients' survival time. Mutation positive populations had shorter survival compared to that of non-mutated patients (supplementary data 8C). Small sample size and relatively shorter followup data may be the limiting factor for getting statistically significant difference of survival rates between the groups of mutated and non-mutated populations in this study.
However, the multiple clinical correlations we noted in this study imply that FAM134B mutations can be used in predicting tumour progression and aggressiveness. All these results concur with the predicted tumour suppressive role of FAM134B in colorectal cancer and the poor prognostic outcomes often suffered following tumour suppressor mutation. In our previous study, we noted that low FAM134B mRNA and protein expression in colorectal carcinoma tissues was significantly associated with larger tumour size and advanced cancer stages. In this study, mutations of FAM134B were linked with larger tumour size, advanced pathological stages, distant metastasis, and poorer clinical outcomes. Therefore, mutations in FAM134B sequences could drive the lower mRNA and protein expression noted in colorectal cancer.
Microsatellite instability (MSI) occurs in 15% of colorectal cancer and results from the inactivation of DNA mismatch repair genes by aberrant methylation and/or by inducing somatic mutations (Pritchard and Grady 2011; Pakneshan et al. 2013) . Metachronous colorectal carcinoma often has positive microsatellite instability (Lam et al. 2012) . In this study, we noted that patients with metachronous colorectal cancers or MSI positive cancers showed more frequent FAM134B mutations. It could be postulated that FAM134B may be involved in the maintenance of genetic integrity or DNA repair and protect against unstable genotype formation.
The clinical features and molecular pathways are often different between cancers from proximal and distal portions of the large intestine (Lam et al. 2008a, b; Saleh et al. 2008; Gopalan et al. 2010; Lam et al. 2011; Alqurashi et al. 2013) . This study noted the largest number of variants (18) of FAM134B in exon 9 and the frequency of those mutations was associated with the site of the cancer in the colorectum (p = 0.031). Approximately one-fourth of the cancer from the proximal colon showed FAM134B exon 9 mutations.
Eight out of twenty-five novel variants detected in the non-coding region of FAM134B in colorectal cancer have the potential to affect the protein features by modifying the splice sites of the gene. In silico (http://www.mutationtaster.org/) analysis revealed that these variants can make the existing splice sites either stronger or weaker leading to changed protein structure and functions. They also have the potential to create additional splice sites or deactivate existing splice sites completely. Thus, mutations in these sites could have the potential to affect gene function, likely as previously reported in neurological disease (Kurth et al. 2009 ).
Using paraffin-embedded cancer tissues, we have previously reported the loss of copy number and reduced expression of FAM134B in colorectal adenocarcinomas (Kasem et al. 2014a, c) . This study reported for the first time that FAM134B mRNA expression is altered, using fresh colorectal adenocarcinoma tissues. Among the FAM134B mutation positive colorectal cancers, more than a third of them showed low FAM134B mRNA expression. We also noted a significant reduction of FAM134B mRNA in cancer tissues when compared to their matched non-neoplastic tissues. These findings were analogous to our previous FAM134B expression profiling results (Kasem et al. 2014a, b, c; Islam et al. 2017) .
BRAF mutation is an independent negative prognostic factor in patients with advanced and recurrent colorectal cancer (Pakneshan et al. 2013 ). In the current study, colorectal cancer with BRAF mutations showed reduced FAM134B expression, suggesting that FAM134B has downstream interactions with BRAF-associated cancer pathways. It was reported that BRAF mutational activation can inactivate the tumour inhibitor PTEN and generate many different types of cancers by inducing hyper-activation of PI3K/AKT and mitogen-activated protein kinase 1 3 (MAPK)-signalling (Rahman et al. 2013 (Rahman et al. , 2014 (Rahman et al. , 2015a (Rahman et al. , b, 2016 . Downregulation of FAM134B may lead to BRAFmediated activation (or vice versa, BRAF mutation may reduce FAM134B expression) of PI3K/AKT and MAPK signalling, and promote colorectal cancer pathogenesis. Further studies incorporating larger numbers of samples as well as functional studies are needed to investigate the association between BRAF mutation and FAM134B expression.
We have investigated FAM134B protein expression in FAM134B mutated and non-mutated cancer by immunofluorescence staining and Western blot analysis. We noted significant reduction/loss of FAM134B protein expression in FAM134B mutated colorectal cancer (Fig. 5) . It has previously been reported that homozygous non-sense mutations (p.S309X, p.Q145X) lead to non-sense-mediated decay resulting in the complete absence of the protein or to a truncated and non-functional gene product occurred in autonomic neuronal disorders (HSAN II) (Kurth et al. 2009 ). In addition, a frameshift (p.P7GfsX133) and an intronic mutation were identified in HSAN patients, which are likely to cause non-sense-mediated decay and loss of protein function. In some colorectal cancers examined in this study, FAM134B had shown mutant variants (p.Thr359Asn, p.Asp349Arg and p.Pro351His), which have the potential to mediate non-sense-mediated decay resulting in loss or reduced expression of FAM134B. Similarly, the variant noted in colon cancer cell lines, p.Ser286Leu, can potentially alter the splice site specificity at the location of the variant, which may be involved in the downregulation of the gene product. Thus, the potentially pathogenic variants detected in the current study could be the possible cause of FAM134B downregulation in colon cancer tissues and cell lines. Further functional studies on particular mutations are needed to confirm their impact on the function and structure of the protein.
In conclusion, this study has, for the first time, reported the existence of multiple novel FAM134B mutation sites in colorectal carcinomas. The downregulation of FAM134B mRNA and protein in colorectal carcinoma might be driven by these mutations. Multiple novel mutant variations in the coding sequence of FAM134B were noted and each of these mutations may contribute to the altered expression or structural and functional changes of the gene, which, in turn, could play an important role in the pathogenesis of colorectal cancer. The variants p.Glu354Glu, p.Val342Ala, p.Thr359Thr, p.Ser276Cys, and p.Asp349Arg fsX13 are the most frequent and common variants identified in colorectal cancer tissues and cell lines. In addition, the identified FAM134B mutations in colorectal cancer were associated with clinical and pathological variables, implying the potential clinical significance of the gene in the cancer.
